Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Amarin Corp Ads (AMRN)

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,333,082
  • Shares Outstanding, K 393,437
  • Annual Sales, $ 614,060 K
  • Annual Income, $ -18,000 K
  • 60-Month Beta 2.35
  • Price/Sales 3.84
  • Price/Cash Flow N/A
  • Price/Book 3.75
Trade AMRN with:

Options Overview

Details
  • Implied Volatility 91.53%
  • Historical Volatility 63.50%
  • IV Percentile 56%
  • IV Rank 17.82%
  • IV High 302.18% on 02/25/21
  • IV Low 45.84% on 09/11/20
  • Put/Call Vol Ratio 0.39
  • Today's Volume 28,425
  • Volume Avg (30-Day) 10,379
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 261,911
  • Open Int (30-Day) 193,339

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.04
  • Number of Estimates 6
  • High Estimate -0.02
  • Low Estimate -0.06
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.03 +0.99%
on 04/13/21
7.30 -30.41%
on 03/17/21
-1.42 (-21.85%)
since 03/12/21
3-Month
5.03 +0.99%
on 04/13/21
9.25 -45.08%
on 02/03/21
-0.88 (-14.77%)
since 01/13/21
52-Week
3.36 +51.19%
on 09/24/20
9.25 -45.08%
on 02/03/21
-1.31 (-20.50%)
since 04/13/20

Most Recent Stories

More News
Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk

Marks first and only EC-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated triglycerides (greater-than or equal to150 mg/dL) and other risk characteristics...

AMRN : 5.08 (-13.01%)
Fifteen Medical Societies Now Recommend Icosapent Ethyl to Reduce Cardiovascular Risk, Further Supporting that VASCEPA(R) is Rapidly Becoming a New Standard of Care

Recent recommendations or guidances, from Canada and Egypt, expand the global recognition of this important therapy and its demonstrated favorable outcomes study results

AMRN : 5.08 (-13.01%)
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular...

HLS.TO : 18.91 (-0.26%)
AMRN : 5.08 (-13.01%)
HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented at International Stroke Conference 2021

HLS Therapeutics Announces that VASCEPA® (Icosapent Ethyl) is Found in Prespecified and Post Hoc Analyses to Significantly Reduce Stroke in At-Risk Patients in Analyses of Landmark REDUCE-IT® Study Presented...

HLS.TO : 18.91 (-0.26%)
AMRN : 5.08 (-13.01%)
Amarin is Now Oversold (AMRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

AMRN : 5.08 (-13.01%)
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

TEVA : 10.76 (-1.65%)
RDY : 62.71 (-4.77%)
AMRN : 5.08 (-13.01%)
SAVA : 36.03 (+0.19%)
First Week of May 21st Options Trading For Amarin

Investors in Amarin Corp plc saw new options begin trading this week, for the May 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value,...

AMRN : 5.08 (-13.01%)
Amarin to Present at Two Upcoming Investor Conferences

Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences...

AMRN : 5.08 (-13.01%)
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's fourth quarter and full year 2020 financial results...

AMRN : 5.08 (-13.01%)
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®

HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®

HLS.TO : 18.91 (-0.26%)
AMRN : 5.08 (-13.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

3rd Resistance Point 5.85
2nd Resistance Point 5.67
1st Resistance Point 5.38
Last Price 5.08
1st Support Level 4.91
2nd Support Level 4.73
3rd Support Level 4.44

See More

52-Week High 9.25
Fibonacci 61.8% 7.00
Fibonacci 50% 6.30
Fibonacci 38.2% 5.61
Last Price 5.08
52-Week Low 3.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar